Estrella Immunopharma Warrant (ESLAW) Financials
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ESLAW SEC filings page.
This page shows Estrella Immunopharma, Inc. Warrant (ESLAW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The latest statements depict a research-led business whose funding structure changed sharply while operating losses remained substantial.
FY2025 R&D reached$10.2M , up149.4% from FY2024, while operating cash flow improved sharply. The gap between a$13.1M net loss and-$1.8M operating cash flow indicates that the reported loss was not translating one-for-one into cash use, even as research spending became the dominant visible operating investment.
Spending shifted toward research: R&D rose
FY2025 liabilities of
Financial Health Signals
Estrella Immunopharma, Inc. Warrant does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Estrella Immunopharma, Inc. Warrant passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Estrella Immunopharma, Inc. Warrant reported a net loss of $13.1M while operations used $1.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Estrella Immunopharma, Inc. Warrant reported a net loss of $2.3M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Estrella Immunopharma, Inc. Warrant earned -$0.05 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Estrella Immunopharma, Inc. Warrant held $100K in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
Estrella Immunopharma, Inc. Warrant invested $1.4M in research and development in Q2 2026. This represents a decrease of 70.0% from the same quarter a year earlier. It is unchanged from the prior quarter.
Not reported for Q2 2026.
Not reported for Q2 2026.
ESLAW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.4M-70.0% | $1.4M-0.7% | N/A | $4.2M+46.9% | $4.7M+32.2% | $1.4M+5540.8% | N/A | $2.8M+484.5% |
| SG&A Expenses | $684K-22.6% | $892K+28.5% | N/A | $649K+17.8% | $884K+108.2% | $694K+56.1% | N/A | $551K-60.3% |
| Operating Income | -$2.1Mn/m | -$2.3Mn/m | N/A | -$4.8Mn/m | -$5.5Mn/m | -$2.1Mn/m | N/A | -$3.4Mn/m |
| Income Tax | N/A | N/A | N/A | N/A | $850-47.7% | $13 | N/A | N/A |
| Net Income | -$2.3Mn/m | -$2.3Mn/m | N/A | -$4.8Mn/m | -$5.5Mn/m | -$2.1Mn/m | N/A | -$3.4Mn/m |
| EPS (Basic) | -$0.05n/m | -$0.05n/m | -$0.01 | -$0.13n/m | -$0.15n/m | -$0.06n/m | N/A | -$0.09 |
| EPS (Diluted) | -$0.05n/m | -$0.05n/m | -$0.01 | -$0.13n/m | -$0.15n/m | -$0.06n/m | N/A | -$0.09 |
| Diluted Shares (Avg) | 43M+18.9% | 42M+16.4% | N/A | 37M+2.5% | 36M-0.6% | 36M+1.9% | N/A | 36M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Interest Expense.
ESLAW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.8M-38.8% | $3.7M+49.6% | $3.2M+1.2% | $3.5M-5.7% | $3.0M-33.1% | $2.4M-71.7% | $3.1M-66.8% | $3.7M-86.3% |
| Current Assets | $1.8M+23.2% | $2.2M+128.5% | $1.7M+2.2% | $2.0M-9.5% | $1.5M-66.8% | $944K-89.1% | $1.6M-82.6% | $2.2M |
| Cash & Equivalents | $100K-92.4% | $1.9M+357.3% | $1.4M+51.0% | $1.6M-9.5% | $1.3M-68.4% | $421K-91.1% | $917K-89.9% | $1.8M-91.9% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $9.3M+2.0% | $8.9M+108.8% | $13.5M+351.9% | $13.4M+347.0% | $9.1M+4922.2% | $4.3M+2987.0% | $3.0M+651.6% | $3.0M-82.7% |
| Current Liabilities | $9.3M+2.0% | $8.9M+108.8% | $13.5M+351.9% | $13.4M+347.0% | $9.1M+4922.2% | $4.3M+2987.0% | $3.0M+651.6% | $3.0M-82.7% |
| Non-Current Liabilities | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Equity | -$7.4Mn/m | -$5.3Mn/m | -$10.4M-7312.1% | -$9.8M-1418.1% | -$6.1M-242.6% | -$1.8M-121.6% | $144K-98.4% | $746K-92.6% |
| Retained Earnings | -$41.6Mn/m | -$39.3Mn/m | -$37.0Mn/m | -$36.4Mn/m | -$31.6Mn/m | -$26.0Mn/m | -$23.9Mn/m | -$22.9Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ESLAW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.8Mn/m | -$6.7Mn/m | -$177Kn/m | -$727Kn/m | -$415Kn/m | -$466Kn/m | -$896Kn/m | -$2.2Mn/m |
| Stock-Based Compensation | $145K-8.7% | $147K-7.8% | N/A | $152Kn/m | $159K | $159K | N/A | $0-100.0% |
| Financing Cash Flow | $4-100.0% | $7.2Mn/m | -$65K-518.8% | $1.0Mn/m | $1.3Mn/m | -$29Kn/m | $15Kn/m | -$150K-100.8% |
| Share Buybacks | N/A | N/A | $0 | $0-100.0% | $0-100.0% | $29K-65.0% | N/A | $150K |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid.
ESLAW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -452.5%-433.9pp |
| Return on Assets | -126.4%+59.6pp | -62.7%+23.4pp | N/A | -136.3%-45.9pp | -186.0%-97.3pp | -86.1%-80.7pp | N/A | -90.4%-83.6pp |
| Current Ratio | 0.200.0x | 0.240.0x | 0.12-0.4x | 0.15-0.6x | 0.16-24.5x | 0.22-62.1x | 0.55-23.1x | 0.75 |
| Liabilities-to-Equity | N/A | N/A | N/A | N/A | N/A | N/A | 20.85+20.8x | 4.00+2.3x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$10.4M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.12), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where Estrella Immunopharma, Inc. Warrant Ranks
Frequently Asked Questions
Is Estrella Immunopharma, Inc. Warrant profitable?
No, Estrella Immunopharma, Inc. Warrant (ESLAW) reported a net loss of $13.1M in fiscal year 2025.
What is Estrella Immunopharma, Inc. Warrant's operating cash flow?
Estrella Immunopharma, Inc. Warrant (ESLAW) recorded an outflow of $1.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Estrella Immunopharma, Inc. Warrant's total assets?
Estrella Immunopharma, Inc. Warrant (ESLAW) had $3.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Estrella Immunopharma, Inc. Warrant spend on research and development?
Estrella Immunopharma, Inc. Warrant (ESLAW) invested $10.2M in research and development during fiscal year 2025.
What is Estrella Immunopharma, Inc. Warrant's current ratio?
Estrella Immunopharma, Inc. Warrant (ESLAW) had a current ratio of 0.12 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Estrella Immunopharma, Inc. Warrant's return on assets (ROA)?
Estrella Immunopharma, Inc. Warrant (ESLAW) had a return on assets of -411.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Estrella Immunopharma, Inc. Warrant's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Estrella Immunopharma, Inc. Warrant (ESLAW) held $1.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $1.8M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Estrella Immunopharma, Inc. Warrant's debt-to-equity ratio negative or not reported?
Estrella Immunopharma, Inc. Warrant (ESLAW) has negative shareholder equity of -$10.4M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Estrella Immunopharma, Inc. Warrant's Piotroski F-Score?
Estrella Immunopharma, Inc. Warrant (ESLAW) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Estrella Immunopharma, Inc. Warrant's earnings high quality?
Estrella Immunopharma, Inc. Warrant (ESLAW) reported a net loss of $13.1M while operations used $1.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.